NewAmsterdam Pharma's Chief Operating Officer Douglas Kling will resign effective August 14, 2026, to become CEO of another clinical-stage biotech company.
| IndividualDouglas Kling | RoleChief Operating Officer | Type of ChangeResignation | Effective DateAugust 14, 2026 | ReasonTo be appointed as CEO of another clinical-stage biotech company (per filing) | Replacement InfoNot disclosed | Background DetailsWill potentially provide transition and advisory services related to PREVAIL trial of obicetrapib and other clinical programs under an expected advisor agreement | Board/Committee Role ChangesNot disclosed |
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.